Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more
Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Total Liabilities
Latest total liabilities as of December 2025: $399.38 Million USD
Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has total liabilities worth $399.38 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biohaven Pharmaceutical Holding Co Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biohaven Pharmaceutical Holding Co Ltd Competitors by Total Liabilities
The table below lists competitors of Biohaven Pharmaceutical Holding Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Freightways Group Ltd
AU:FRW
|
Australia | AU$901.75 Million |
|
DBG Technology Co Ltd Class A
SHE:300735
|
China | CN¥4.51 Billion |
|
Hufvudstaden AB (publ)
PINK:HUFAF
|
USA | $22.33 Billion |
|
Dongguan Yiheda Automation Co. Ltd.
SHE:301029
|
China | CN¥633.38 Million |
|
Flight Centre Travel Group Ltd
AU:FLT
|
Australia | AU$3.47 Billion |
|
Thai Life Insurance PCL
BK:TLI
|
Thailand | ฿505.29 Billion |
|
C*Core Technology Co Ltd
SHG:688262
|
China | CN¥1.18 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Biohaven Pharmaceutical Holding Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biohaven Pharmaceutical Holding Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
The table below shows the annual total liabilities of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $399.38 Million | +108.36% |
| 2024-12-31 | $191.67 Million | +124.87% |
| 2023-12-31 | $85.24 Million | -30.71% |
| 2022-12-31 | $123.01 Million | +159.68% |
| 2021-12-31 | $47.37 Million | +36.44% |
| 2020-12-31 | $34.72 Million | -90.13% |
| 2019-12-31 | $351.69 Million | +152.85% |
| 2018-12-31 | $139.09 Million | +832.44% |
| 2017-12-31 | $14.92 Million | -- |